No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Diagnostics & Research
IQVIA Holdings Inc. is a global leader empowering the life sciences sector with advanced analytics, innovative technology solutions, and comprehensive clinical research services. Operating across the Americas, Europe, Africa, and the Asia-Pacific regions, its capabilities are organized into three main divisions. Within its Technology & Analytics Solutions segment, IQVIA delivers cloud-based applications alongside essential implementation services. It also specializes in real-world solutions, enabling clients to generate and disseminate crucial evidence that informs healthcare decisions and ultimately enhances patient outcomes. This segment extends its expertise to strategic and implementation consulting, encompassing advanced analytics and commercial process outsourcing. Furthermore, it furnishes comprehensive market performance data, tracking pharmaceutical sales, prescribing trends, treatment efficacy, and promotional activities at a granular level – from country-wide views down to regional, zip code, and individual prescriber insights, across diverse channels like retail, hospital, and mail order. The Research & Development Solutions segment offers a broad spectrum of support for clinical trials, from initial strategic planning and design to meticulous project management and clinical monitoring, including innovative virtual trial capabilities. Complementing these, it provides an extensive array of laboratory services, such as central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment focuses on engaging healthcare providers and patients, alongside offering scientific strategy and medical affairs support. IQVIA's client base spans pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. Additionally, the firm maintains a strategic alliance with HealthCore, Inc. Founded in 1982, the company was initially known as Quintiles IMS Holdings, Inc., before rebranding as IQVIA Holdings Inc. in November 2017. Its corporate headquarters are situated in Durham, North Carolina.
www.iqvia.comNo one on the platform currently holds 0JDM.L.
No tracked institution reports a position in 0JDM.L as of their last filing.
No one on the platform has traded 0JDM.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 9.3% | 8.8% | 7.6% | — | — | — |
| Rev. Growth % | 5.9% | 7.5% | ||||
| Profit Margin % | 8.3% | 8.2% | 6.2% | |||
| Free Cash Flow Margin % | 12.6% | 12.8% | 10.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $17.4B | +7.6% | $12.97 | $12.86–$13.30 | — | 1 |
| 2027 | $18.4B | +5.8% | $14.42 | $14.30–$14.79 | — | 1 |
| 2028 | $19.5B | +5.9% | $16.15 | $16.01–$16.56 | — | 1 |
| 2029 | $20.8B | +6.7% | $18.31 | $18.16–$18.78 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-28 | $3.03 | $3.15 | +4.0% |
| 2026-05-05 | $2.82 | $2.90 | +2.8% |
| 2026-02-05 | $3.40 | $3.42 | +0.6% |
| 2025-10-28 | $2.98 | $3.00 | +0.7% |
| 2025-07-22 | $2.77 | $2.81 | +1.4% |
| 2025-05-06 | $2.63 | $2.70 | +2.7% |
| 2025-02-06 | $3.11 | $3.12 | +0.3% |
| 2024-10-31 | $2.82 |
| $2.84 |
| +0.7% |
| $47.5B |
| — |
| 0J8Z.LIllumina, Inc. | $226.40 | +8.85% | $34.3B | — |
| 0J9P.LIncyte Corporation | $121.28 | -0.97% | $24.0B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.